A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...
CNN1y
AbbVie, Inc.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune ...
Nasdaq3d
AbbVie a Top 25 Dividend Giant With 3.85% Yield (ABBV)
AbbVie Inc (Symbol: ABBV ... Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. Indeed, studying a company's past dividend history can ...
AbbVie price target lowered to $205 from $215 at Citi
Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...